meRfi®-GM
Fidaxomicin & Clostridioides difficile infection (CDI) (recurrent)
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
References (Sources)
- Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent Clostridium difficile infection
- Fidaxomicin versus vancomycin for Clostridium difficile infection
- Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial
- Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin